Cassava Sciences Announces New Patent Grant

Rhea-AI Summary

Cassava Sciences, Inc. (SAVA) announced the granting of U.S. Patent No. 10,760,052 on September 1, 2020, related to inhibiting TLR4-mediated immune responses using filamin A binding molecules. This adds to their growing patent portfolio, which now includes seven issued patents extending through 2037. The company’s main drug candidate, sumifilam, aims to treat Alzheimer's disease by restoring altered filamin A function in the brain. Cassava retains worldwide rights for its developments in Alzheimer’s without royalty obligations, reinforcing its position in this critical therapeutic area.

Positive

• Granting of U.S. Patent No. 10,760,052 strengthens intellectual property protection for Cassava's lead drug candidate, sumifilam.
• The patent portfolio now includes seven issued patents, extending protection through 2037.
• Cassava owns worldwide rights to sumifilam and related technologies without royalty obligations.

Negative

• None.

AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it was granted U.S. Patent No. 10,760,052 on September 1, 2020. These patent claims are directed to inhibiting a TLR4-mediated immune response though use of one or more unique filamin A binding molecules.

Cassava Sciences’ lead drug candidate, sumifilam, is a novel molecule. The Company’s patent protection in the area of filamin-binding molecules currently runs through 2037, plus extensions, and now includes seven issued patents plus related patent filings and applications.

Sumifilam was discovered in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third-party.

About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. In the U.S. alone, approximately 5.8 million people are currently living with Alzheimer’s disease, and approximately 487,000 people age 65 or older developed Alzheimer’s in 2019.¹ The number of people living with Alzheimer’s disease is expected to grow dramatically in the years ahead, resulting in a growing social and economic burden.²

^{________________
1, 2} Source: Alzheimer’s Association. 2019 Alzheimer’s Disease Facts and Figures. Available online at: https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf

About Sumifilam (formerly, PTI-125)
Cassava Sciences’ lead therapeutic product candidate is for the treatment of Alzheimer’s disease.  Sumifilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science is published in peer-reviewed scientific journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease.

About SavaDx
SavaDx is Cassava Sciences’ investigational diagnostic to detect Alzheimer’s disease. The goal of SavaDx is to make the detection of Alzheimer’s as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.  

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and   develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. Both sumifilam and SavaDx are substantially funded by research grant awards from the National Institutes of Health.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:                  
Eric Schoen, Chief Financial Officer              
Cassava Sciences, Inc.                                    
eschoen@CassavaSciences.com                    
(512) 501-2450 

FAQ

What is the significance of U.S. Patent No. 10,760,052 for Cassava Sciences (SAVA)?

The patent strengthens Cassava's intellectual property for its drug candidate sumifilam, enhancing its market position in treating Alzheimer's disease.

How many patents does Cassava Sciences currently hold?

Cassava Sciences has seven issued patents related to filamin A binding molecules, with protection extending through 2037.

What is sumifilam and how does it relate to Alzheimer's disease?

Sumifilam is Cassava Sciences' lead drug candidate aimed at treating Alzheimer's disease by restoring the function of altered filamin A in the brain.

Does Cassava Sciences have any royalty obligations for sumifilam?

No, Cassava Sciences owns worldwide development and commercial rights to sumifilam without any royalty obligations to third parties.